Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia

Kuçur, Mine; İşman, Ferruh Kemal; Balcı, Can; Önal, Bülent; Hacıbekiroğlu, Münire; Özkan, Ferda; Özkan, Adem

doi:10.1016/j.urolonc.2007.07.020

Cited by 45 publications

(34 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased abundance of this protein in all likelihood is not specific for conversion of CIS to MScl or response to natalizumab treatment in MScl patients, but rather a marker for inflammatory activity in the affected compartment, which is supported by the observation of increased levels in serum of several types of cancers and diseases such as rheumatoid arthritis [20][21][22] .…”

Section: Discussionmentioning

confidence: 99%

Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients

et al. 2013

View full text Add to dashboard Cite

Natalizumab is a very effective, relatively new drug for the treatment of relapsing remitting multiple sclerosis. Inflammatory and neurodegenerative processes in the central nervous system are presumed to cause adverse effects during the course of this disease. To monitor the effects of natalizumab treatment on the cerebrospinal fluid (CSF) proteome of patients, CSF samples were taken from patients before commencing treatment as well as after 1 year of treatment. Profiling proteomics experiments using electrospray Orbitrap mass spectrometry and pair wise comparison of patients before and after 1 year of natalizumab treatment revealed a number of candidate biomarkers that were significantly differentially abundant between the before and after treatment groups. Three proteins were subsequently validated using selected reaction monitoring (SRM) in a new, independent sample set. All three proteins, Ig mu chain C region and haptoglobin, both known inflammation-related proteins, as well as Chitinase-3-like protein 1, were confirmed by SRM to be significantly lower abundant in CSF of multiple sclerosis patients after 1 year of natalizumab treatment. The findings for Chitinase-3-like protein 1, a presumed biomarker for more rapid progression from a first clinically isolated syndrome to clinically definite multiple sclerosis, was further confirmed by ELISA measurements.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Macrophages in tumor stroma have also been shown to express CHi3L1 which likely also promotes tumor angiogenesis [24] . Blood levels of CHi3L1 are negligible under normal physiologic conditions, however, elevated blood levels of CHi3L1 have been found in patients with chronic inflammatory conditions [25] and a wide variety of cancers including colorectal [22,26] , breast [27] , prostate [28] , lung [29,30] , thyroid [31] , endometrial [32] pancreatic [33] hepatocellular [34] , ovarian [35] , gastric cancer [36] , and malignant melanoma [37] . Additionally, for the majority of these malignancies, a correlation has been demonstrated between blood levels of CHi3L1 and a poor prognosis [26,[29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] .…”

Section: Introductionmentioning

confidence: 99%

Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection

Kumara

Gaita

Miyagaki

et al. 2016

WJGO

View full text Add to dashboard Cite

AIM:To assess blood chitinase 3-like 1 (CHi3L1) levels for 2 mo after minimally invasive colorectal resection (MICR) for colorectal cancer (CRC). METHODS: CRC patients in an Institutional ReviewBoard approved data/plasma bank who underwent elective MICR for whom preoperative (PreOp), early postoperative (PostOp), and 1 or more late PostOp samples [postoperative day (POD) 7-27] available were included. Plasma CHi3L1 levels (ng/mL) were determined in RESULTS:PreOp and PostOp plasma sample were available for 80 MICR cancer patients for the study. The median PreOp CHi3L1 level was 56.8 CI: 41.9-78.6 ng/ mL (n = 80). Significantly elevated (P < 0.001) median plasma levels (ng/mL) over PreOp levels were detected on POD1 (667.7 CI: 495.7, 771.7; n = 79), POD 3 (132.6 CI: 95.5, 173.7; n = 76), 136.9; n = 62), 287.4; n = 22), 137.4; n = 20, P = 0.001).No significant difference in plasma levels were noted on POD27-41.CONCLUSION: Plasma CHi3L1 levels were significantly elevated for one month after MICR. Persistently elevated plasma CHi3L1 may support the growth of residual tumor and metastasis.

show abstract

“…Enhanced serum levels of YKL-40 were detected in various cancers, such as glioblastoma, colorectal breast, kidney and ovary cancer [14,23] with highest levels in distant metastatic stages (renal cell cancer: 235 ng/mL, breast cancer: 65-80 ng/mL, colorectal cancer: 119 ng/ mL, malignant melanoma: 95 ng/mL, PCa: 141 ng/mL) [24]. Kucur et al [25] demonstrated elevated serum YKL- 40 levels in patients with primary PCa but not in benign prostatic hyperplasia. In contrast, Kjaergaard et al [26] found that YKL-40 levels measured in healthy individuals were not associated with later development of PCa.…”

Section: Discussionmentioning

confidence: 99%

The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer

et al. 2018

View full text Add to dashboard Cite

Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer patients who underwent DOC-therapy. Responsive patients were retreated by repeated series of DOC. Results were compared with the clinical parameters as well as overall (OS) and disease-specific survival (DSS). Results: YKL-40 but not PSA serum levels were significantly higher in patients with baseline resistance to DOC (p = 0.035). Higher YKL-40 and PSA levels were detected in patients with bone metastasis (p = 0.032; p = 0.010) and in those who were not pre-treated with radical prostatectomy (p = 0.011, p = 0.008). High YKL-40 levels were associated with shorter OS (p = 0.037) and DSS (p = 0.017) in patients who received DOC in the first-line setting. In multivariable analysis, ECOG performance status (p = 0.009), presence of any metastases (p = 0.016) and high PSA levels (p = 0.005) remained independent predictors for DSS. Conclusions: YKL-40 may help to identify patients with baseline resistance to DOC and therefore may help to optimize treatment decisions. In accordance, high pre-treatment YKL-40 serum levels were associated with shorter OS and DSS in patients who received DOC as first-line therapy.

show abstract

Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia

Cited by 45 publications

References 39 publications

Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients

Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients

Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection

The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer

Contact Info

Product

Resources

About